2021 Q4 IngenioRx Drug & Biologic Pipeline Update

January 19, 2022 | Download PDF
Image

 

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals. This newsletter analyzes drugs and biologics in development. Open the attachment to learn about:

 

Emerging therapies for the treatment of vasomotor symptoms associated with menopause, severe asthma, and hypertrophic cardiomyopathy.

 

Evaluate significant product approvals, including biosimilars expected in 2021 and 2022.

 

Offer insights on the current gene therapy pipeline.

 

The latest on psoriasis and migraine pipelines.

 

 

Stay up to date with the latest from IngenioRx